Pedro Berraondo

55PUBLICATIONS
156CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (55)

|Aug 06, 2026
Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors.

|Dec 10, 2025
Trispecific engager overcomes tumoural immunosuppressive environment.

Fernando Aranda, Aline Risson, Pedro Berraondo

|Dec 02, 2025
Facts and Hopes in Harnessing Macrophage-Mediated Antibody-Dependent Cellular Phagocytosis for Cancer Immunotherapy.

Maria Armero, Manuel Smolkin, Mario Garcia-Dominguez

|Jun 24, 2025
The long-lasting expression of recombinant artLCMV following intraperitoneal administration exerts potent antitumor effects on tumor models of peritoneal carcinomatosis.

Celia Gomar, Aline Risson, Leire Arrizabalaga

|Jun 10, 2025
Combining local cytokine delivery and systemic immunization with recombinant artLCMV boosts antitumor efficacy in several preclinical tumor models.

Kimberly Pojar, Diana Reckendorfer, Judith Strauss

|Apr 29, 2025
Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.

Juan F Rodríguez-Moreno, Guillermo de Velasco, Carlos Álvarez-Fernández

Pageof 10

Frequent Collaborators

26 joint publications

Ignacio Melero

12 joint publications

Álvaro Teijeira

9 joint publications

Iñaki Eguren-Santamaria

7 joint publications

Carlos Luri-Rey